Medicenna Therapeutics (MDNA) KOL Event summary

Introduction and agenda

• The event presented updated clinical data from the ABILITY-1 Phase 1/2 study of MDNA11 in advanced solid tumors, including monotherapy and combination with checkpoint inhibitors, and was discussed at ESMO Immuno-Oncology Congress 2025.

• The agenda covered trial design, patient characteristics, safety, efficacy, mechanistic insights, future development plans, principal investigator perspectives, KOL commentary, and Q&A.

• Webinar hosted with management, principal investigator, and key opinion leaders to discuss results and future directions.

KOL background and credentials

• Key opinion leaders included Dr. Hussein Tawbi (MD Anderson), Dr. Igor Puzanov (Roswell Park), Dr. Paolo Ascierto (Naples), Dr. Toni Choueiri (Dana-Farber), and principal investigator Dr. André Mansinho, all with expertise in immuno-oncology and drug development.

Market insights and analysis

• MDNA11 is a β-enhanced, not-α IL-2 superagonist in clinical development for advanced solid tumors, with both monotherapy and combination arms (with pembrolizumab/KEYTRUDA).

• The molecule's unique receptor engagement and clean safety profile differentiate it from other IL-2 variants, addressing unmet needs in refractory and ICI-resistant solid tumors.

• MDNA11 shows durable anti-tumor activity in checkpoint-resistant melanoma, MSS endometrial, MSI-H, and TMB-H cancers, exceeding ORR benchmarks in these populations.

• External validation from the NEO-CYT trial in high-risk melanoma supports the approach and potential for earlier-stage patients.